Zydus Lifesciences Introduces Overactive Bladder Treatment Tablet in US Market

Services

Stock Market Masterclass

Equity Trading with CA Abhay

Equity Investment with CA Abhay

FNO Stocks with CA Abhay

Option Trading with CA Abhay

Zydus Lifesciences Introduces Overactive Bladder Treatment Tablet in US Market

Team FS

22/Apr/2024

Key Points:

New Treatment for Overactive Bladder: Zydus Lifesciences Ltd. introduces Mirabegron Extended-Release tablets, 25 mg, in the US market, offering relief for overactive bladder symptoms.
USFDA Approval: The tablet received final approval from the United States Food and Drug Administration (USFDA), making Zydus one of the first suppliers to launch the generic version of this medication.
Expansion in the US Market: The launch strengthens Zydus' presence in the US pharmaceutical market and enhances accessibility to this essential medication for patients.

Zydus Lifesciences Ltd. has unveiled a new tablet, Mirabegron Extended-Release 25 mg, targeting the treatment of overactive bladder symptoms in the United States. The company's latest offering aims to address the discomfort associated with urge urinary incontinence, urgency, and urinary frequency, providing relief to patients suffering from this condition.

New Treatment for Overactive Bladder: Mirabegron, the active ingredient in the tablet, is specifically indicated for the treatment of overactive bladder, offering a solution to individuals experiencing symptoms such as urinary urgency, frequent urination, and urge urinary incontinence. With the launch of Mirabegron Extended-Release tablets, Zydus aims to expand treatment options and improve the quality of life for patients dealing with overactive bladder issues.

USFDA Approval and Market Impact: Zydus Lifesciences Ltd. secured final approval from the United States Food and Drug Administration (USFDA) for the marketing of Mirabegron Extended-Release Tablets USP 25 mg and 50 mg. By introducing the generic version of the 25 mg tablet, Zydus demonstrates its commitment to providing affordable healthcare solutions to patients in need. The company is poised to further bolster its presence in the US pharmaceutical market with imminent plans to launch the 50 mg variant.

Expansion and Growth Plans: Punit Patel, CEO Americas at Zydus Lifesciences Ltd., highlighted the significance of the Mirabegron launch in enhancing patient access and availability of this vital medication in the US market. The introduction of Mirabegron aligns with Zydus' growth strategy, reinforcing its position as a key player in the pharmaceutical industry. With an extensive portfolio of products and a robust pipeline of innovative therapies, Zydus continues to drive advancements in healthcare delivery and patient care.

The launch of Mirabegron Extended-Release tablets marks a significant milestone for Zydus Lifesciences Ltd. as it expands its footprint in the competitive US pharmaceutical market. With a focus on providing affordable and accessible healthcare solutions, Zydus reaffirms its commitment to improving patient outcomes and addressing unmet medical needs. As the company continues to innovate and grow, it remains poised to make a meaningful impact on global healthcare.

Also Read : China Maintains Stability in Loan Prime Rate Amid Improving Economic Conditions

Join our Telegram Channel and WhatsApp Channel for regular Updates.

Services

Zydus Lifesciences Introduces Overactive Bladder Treatment Tablet in US Market

Related News